A Time for MYC: Metabolism and Therapy.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Cold Spring Harbor Symposia on Quantitative Biology

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1101/sqb.2016.81.031153PMID 28174256
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• MYC/MIZ1-dependent gene repression inversely coordinates the circadian clock with cell cycle and proliferation

  2016cited by this paper
• Environment Impacts the Metabolic Dependencies of Ras-Driven Non-Small Cell Lung Cancer.

  2016cited by this paper
• Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) as a therapeutic strategy in cancer.

  2015cited by this paper
• MYC Disrupts the Circadian Clock and Metabolism in Cancer Cells.

  2015cited by this paper
• Taming of the beast: shaping Myc-dependent amplification.

  2015cited by this paper
• MYC: connecting selective transcriptional control to global RNA production

  2015cited by this paper
• Targeted inhibition of tumor-specific glutaminase diminishes cell-autonomous tumorigenesis.

  2015cited by this paper
• MYC, Metabolism, and Cancer.

  2015cited by this paper
• Protein and nucleotide biosynthesis are coupled by a single rate-limiting enzyme, PRPS2, to drive cancer.

  2014cited by this paper
• Targeting lactate dehydrogenase--a inhibits tumorigenesis and tumor progression in mouse models of lung cancer and impacts tumor-initiating cells.

  2014cited by this paper
• MYC, metabolism, cell growth, and tumorigenesis.

  2013cited by this paper
• Isotopically nonstationary 13C flux analysis of Myc-induced metabolic reprogramming in B-cells.

  2013cited by this paper
• ER stress-mediated autophagy promotes Myc-dependent transformation and tumor growth.

  2012cited by this paper
• MYC on the path to cancer.

  2012cited by this paper
• mTOR signaling in growth control and disease.

  2012cited by this paper
• Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells.

  2012cited by this paper
• Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression

  2010cited by this paper

• Circ_0001839 modulates the oncogenic MYCL rs1038259890 (p.G83S) mutation to promote B[a]P-induced malignant transformation in 16HBE cells.

  2026cites this paper
• Axes of biological variation in diffuse large B cell lymphoma.

  2026cites this paper
• Regulatory role of transcription factor c-Myc in the pathogenesis of psoriasis

  2025cites this paper
• RB1 controls differentiation through positive regulation of phosphoglycerate mutases

  2025cites this paper
• Targeting miR-32-5p suppresses c-MYC-driven proliferation and induces apoptosis in MCF-7 breast cancer cells

  2025influential citation
• STK32C promotes colon tumor progression through activating c-MYC signaling

  2025cites this paper
• A Potential Role for c-MYC in the Regulation of Meibocyte Cell Stress

  2025cites this paper
• Molecular mechanisms of viral oncogenesis in haematological malignancies: perspectives from metabolic reprogramming, epigenetic regulation and immune microenvironment remodeling

  2025cites this paper
• Citrate oscillations during cell cycle are a targetable vulnerability in cancer cells.

  2025cites this paper
• Comprehensive PTM profiling with SCASP-PTM uncovers mechanisms of p62 degradation and ALDOA-mediated tumor progression.

  2025cites this paper
• Investigating the Mechanism of IFN‐γ‐Inducible Lysosomal Thiol Reductase‐Mediated Inhibition of Breast Cancer Cell Proliferation

  2025cites this paper
• A prognostic model based on autophagy-and senescence-related genes for gastric cancer: implications for immunotherapy and personalized treatment

  2025cites this paper
• The Effect of Myc Inhibition Combined with the Synergistic Effect of Photothermal, Photodynamic and Radiotherapy in Tumor Treatment

  2025cites this paper
• Targeting MYC: Multidimensional regulation and therapeutic strategies in oncology

  2024cites this paper
• mTORC1, the maestro of cell metabolism and growth

  2024cites this paper
• Regulation of lipid and serine metabolism by the oncogene c-Myc.

  2024cites this paper
• Dysfunction of Calcyphosine-Like gene impairs retinal angiogenesis through the MYC axis and is associated with familial exudative vitreoretinopathy

  2024cites this paper
• F-ATP synthase inhibitory factor 1 and mitochondria-organelle interactions: new insight and implications.

  2024cites this paper
• Nilotinib: Disrupting the MYC-MAX Heterocomplex

  2024cites this paper
• Recent Discovery and Development of Inhibitors that Target CDK9 and Their Therapeutic Indications.

  2024cites this paper
• The mTORC2 signaling network: targets and cross-talks

  2024cites this paper
• A second-generation eIF4A RNA helicase inhibitor exploits translational reprogramming as a vulnerability in triple-negative breast cancer

  2024cites this paper
• The Novel Artemisinin Dimer Isoniazide ELI-XXIII-98-2 Induces c-MYC Inhibition, DNA Damage, and Autophagy in Leukemia Cells

  2023cites this paper
• A general method for quantitative fractionation of mammalian cells

  2023cites this paper
• The role of TXNIP in cancer: a fine balance between redox, metabolic, and immunological tumor control

  2023cites this paper
• Unraveling MYC’s Role in Orchestrating Tumor Intrinsic and Tumor Microenvironment Interactions Driving Tumorigenesis and Drug Resistance

  2023cites this paper
• Anlotinib combined with osimertinib reverses acquired osimertinib resistance in NSCLC by targeting the c-MET/MYC/AXL axis.

  2023cites this paper
• The study of an anoikis-related signature to predict glioma prognosis and immune infiltration

  2023cites this paper
• F-ATP synthase inhibitory factor 1 regulates metabolic reprogramming involving its interaction with c-Myc and PGC1α

  2023cites this paper
• mTOR inhibition suppresses Myc-driven polyposis by inducing immunogenic cell death

  2023cites this paper
• Targeting Myc-driven stress addiction in colorectal cancer.

  2023cites this paper
• Acquired Radiation Resistance Induces Thiol-dependent Cisplatin Cross-resistance

  2023cites this paper
• High-Throughput Sequencing Reveals Transcriptome Signature of Early Liver Development in Goat Kids

  2022cites this paper
• Current strategies and progress for targeting the “undruggable” transcription factors

  2022cites this paper
• Methionine Metabolism Controls the B-cell EBV Epigenome and Viral Latency

  2022cites this paper
• Targeting Myc-driven stress vulnerability in mutant KRAS colorectal cancer

  2022cites this paper
• Efficient Identification of the MYC Regulator with the Use of the CRISPR Library and Context-Matched Database Screenings

  2022cites this paper
• The roles of glycolysis in osteosarcoma

  2022cites this paper
• ECE2 is a prognostic biomarker associated with m6A modification and involved in immune infiltration of lung adenocarcinoma

  2022cites this paper
• MYC as a target for cancer treatment.

  2021cites this paper
• Construction and Validation of a Potent Epigenetic Modification-Related Prognostic Signature for Osteosarcoma Patients

  2021cites this paper
• USP29 coordinates MYC and HIF1α stabilization to promote tumor metabolism and progression

  2021cites this paper
• Oxygen as a Master Regulator of Human Pluripotent Stem Cell Function and Metabolism

  2021cites this paper
• The role of mTOR in age-related diseases

  2021cites this paper
• Localized inhibition of protein phosphatase 1 by NUAK1 promotes spliceosome activity and reveals a MYC-sensitive feedback control of transcription

  2021cites this paper
• Measuring MYC-Mediated Metabolism in Tumorigenesis.

  2021cites this paper
• LncRNA MNX-AS1 combined with YBX1 to promote bladder cancer proliferation, migration, and invasion through activiting Wnt signaling pathway

  2021cites this paper
• Tumor starvation by deprivation of glutamine and aspartate

  2021cites this paper
• Metabolic Heterogeneity of Cancer Cells: An Interplay between HIF-1, GLUTs, and AMPK

  2020cites this paper
• Amino Acid Transporters Are a Vital Focal Point in the Control of mTORC1 Signaling and Cancer

  2020cites this paper
• eIF4E S209 phosphorylation licenses myc- and stress-driven oncogenesis

  2020cites this paper
• The novel low molecular weight MYC antagonist MYCMI-6 inhibits proliferation and induces apoptosis in breast cancer cells

  2020cites this paper
• Drugging “undruggable” genes for cancer treatment: Are we making progress?

  2020cites this paper
• Metabolic Heterogeneity of Cancer Cells: An Interplay between Reprogrammed and Oxidative Metabolism and Roles of HIF-1, GLUTs and AMPK

  2020cites this paper
• Localized Inhibition of Protein Phosphatase 1 by NUAK1 Promotes Spliceosome Activity and Reveals a MYC-Sensitive Feedback Control of Transcription

  2020cites this paper
• Interconnection between Metabolism and Cell Cycle in Cancer.

  2019cites this paper
• Targeting mTOR and Metabolism in Cancer: Lessons and Innovations

  2019cites this paper
• Metformin in Cervical Cancer: Metabolic Reprogramming

  2019cites this paper
• A 23 gene–based molecular prognostic score precisely predicts overall survival of breast cancer patients

  2019cites this paper
• Starve Cancer Cells of Glutamine: Break the Spell or Make a Hungry Monster?

  2019cites this paper
• MYC as a therapeutic target for the treatment of triple-negative breast cancer: preclinical investigations with the novel MYC inhibitor, MYCi975

  2019cites this paper
• Glutaminase inhibitor CB-839 increases radiation sensitivity of lung tumor cells and human lung tumor xenografts in mice

  2019cites this paper
• Cooperative STAT/NF-κB signaling regulates lymphoma metabolic reprogramming and aberrant GOT2 expression

  2018cites this paper
• MYC Induces a Hybrid Energetics Program Early in Cell Reprogramming

  2018cites this paper
• BET inhibitors reduce cell size and induce reversible cell cycle arrest in AML

  2018cites this paper
• Revisiting the role of metabolism during development

  2018cites this paper
• Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92.

  2018cites this paper
• MYC-induced metabolic stress and tumorigenesis.

  2018cites this paper
• Targeting oncogenic Myc as a strategy for cancer treatment

  2018cites this paper
• YBX1 promotes tumor growth by elevating glycolysis in human bladder cancer

  2017cites this paper
• c‐MYC mRNA tail tale about glutamine control of transcription

  2017cites this paper